DEMBREXINE HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H17Br2NO2.ClH
Molecular Weight	415.549
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.O[C@H]1CC[C@@H](CC1)NCC2=C(O)C(Br)=CC(Br)=C2

InChI

InChIKey=BGRWLVRJIPTKQW-PFWPSKEQSA-N

InChI=1S/C13H17Br2NO2.ClH/c14-9-5-8(13(18)12(15)6-9)7-16-10-1-3-11(17)4-2-10;/h5-6,10-11,16-18H,1-4,7H2;1H/t10-,11-;

HIDE SMILES / InChI

Description
Sources: http://files.boehringer.com.au/files/CMI/Sputolysin%20AU.pdf
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/3363832 | http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500013623.pdf

Dembrexine is a mucolytic agent which reduces the viscosity of respiratory mucus. It improves movement of mucus in small airways. Dembrexine increases secretion of the serous cells in the glands of the nasal, tracheal and bronchial cells and in type II alveolar cells. It also possesses an anti-tussive effect. Dembrexine is used in the treatment of respiratory disease in horses. All respiratory infections with increased secretions. Acute, sub-acute bronchitis. Chronic respiratory disease. Infection of the upper airways.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
surfactant homeostasis 7 Target ID: GO:0043129 Sources: http://files.boehringer.com.au/files/CMI/Sputolysin%20AU.pdf	Activator 1430

Conditions

Condition	Modality	Highest Phase	Product
Bronchitis 51 Sources: http://files.boehringer.com.au/files/CMI/Sputolysin%20AU.pdf	Palliative	Approved 8429	Sputolosin Approved Use The drug is indicated for the treatment of respiratory disease in horses. All respiratory infections with increased secretions. Acute, sub-acute bronchitis. Chronic respiratory disease. Infection of the upper airways.
Infection of the upper airways 3 Sources: http://files.boehringer.com.au/files/CMI/Sputolysin%20AU.pdf	Palliative	Approved 8429	Sputolosin Approved Use The drug is indicated for the treatment of respiratory disease in horses. All respiratory infections with increased secretions. Acute, sub-acute bronchitis. Chronic respiratory disease. Infection of the upper airways.
Chronic respiratory disease 3 Sources: http://files.boehringer.com.au/files/CMI/Sputolysin%20AU.pdf	Palliative	Approved 8429	Sputolosin Approved Use The drug is indicated for the treatment of respiratory disease in horses. All respiratory infections with increased secretions. Acute, sub-acute bronchitis. Chronic respiratory disease. Infection of the upper airways.
Foal pneumonia 3 Sources: http://files.boehringer.com.au/files/CMI/Sputolysin%20AU.pdf	Palliative	Approved 8429	Sputolosin Approved Use The agent is indicated for the treatment of foal pneumonia.

PubMed

Title	Date	PubMed
The trans-cis isomerization of trans-4'-(2-hydroxy-3,5-dibromo-benzylamino)cyclohexanol in vivo and in vitro in different species.	1986 Jul	3751117
The mucolytic effect of Sputolosin in horses with respiratory disease.	1988 Jan 30	3363832

Patents

Sample Use Guides

In Vivo Use Guide

Twice daily administration of 0.3 mg active ingredient per kg bodyweight. Adult horses (500 kg): 30 g powder twice daily in the food. Small horses, ponies and foals: 10 g powder per 170 kg bodyweight twice daily.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Name

Type

Language

DEMBREXINE HYDROCHLORIDE

Common Name

English

PHENOL, 2,4-DIBROMO-6-(((4-HYDROXYCYCLOHEXYL)AMINO)METHYL)-, HYDROCHLORIDE, TRANS-

Common Name

English

TRANS-4-((3,5-DIBROMO-2-HYDROXYBENZYL)AMINO)CYCLOHEXANOL HYDROCHLORIDE

Systematic Name

English

Classification Tree Code System Code

WHO-VATC

QR05CB90